Clinical Trials Update: Jan. 31, 2007
Breast Cancer or Memory Loss Ovarian Cancer Depression
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
Breast Cancer or Memory Loss
This is a nationwide study for people with breast cancer (either post-chemotherapy or undergoing chemotherapy) who report cognitive decline. Volunteers 21 or older may qualify who have a diagnosis of breast cancer with a self-report of cognitive decline, have a computer that meets certain system requirements, and do not have a history of major neurological illness including but not limited to: Alzheimer's disease, Parkinson's disease, multiple sclerosis or amyotrophic lateral sclerosis.
The research sites are located across the United States.
ZK-Epo is an epothilone, a new class of chemotherapy that has demonstrated success against ovarian cancer and other tumor types in pre-clinical studies. Women 18 or older may be included in this study of the drug who have stage 4 ovarian cancer; fallopian tube cancer; or peritoneal cavity cancer; have progressive disease following previous chemotherapy, and are not currently pregnant or breastfeeding.
The research sites are located across the United States and Canada.
This is a clinical research study of an investigational medication for depression. To qualify, you must be a post-menopausal woman, age 40 to 70, with symptoms of depression. Participants will receive study-related care, exams, and study medication at no cost, as well as compensation of up to $950 for time and travel.
The research site is in Denver, Colo.
Copyright 2007 Thomson CenterWatch. All rights reserved.